Treatment for advanced cervical cancer is limited, but the therapeutic HPV vaccine shows promise as a possible treatment option. In this study, published in Biomaterials, researchers constructed a novel HPV nanovaccine and tested its ability to inhibit cervical cancer progression in mice. This HPV vaccine therapy is novel because it combines nanotechnology and photodynamic therapy, which the researchers hypothesized would result in a more robust immune response.
Ultimately, this HPV nanovaccine was found to have slow-release properties and targeted delivery to lymph nodes that, when combined with the infrared laser irradiation of photosensitizers, seemed to result in enhanced antitumor immunity in mice that effectively inhibited cervical cancer progression.
This study highlights the potential HPV nanovaccines may hold in treating advanced cervical cancer. However, successful translation of this research to benefit people with advanced cervical cancer remains to be seen .
Source: Zhang, L., Wang, K., Huang, Y., Zhang, H., Zhou, L., Li, A., & Sun, Y. (2022). Photosensitizer-induced HPV16 E7 nanovaccines for cervical cancer immunotherapy. Biomaterials, 282, 121411. https://doi.org/10.1016/j.biomaterials.2022.121411